SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix shares are under significant pressure following a quarterly earnings report that featured soft guidance for the second quarter and the surprise announcement that co-founder Reed Hastings will step down from the board. While the company beat on headline earnings and revenue, community sentiment is sharply divided between investors viewing the sell-off as a buying opportunity in a market leader and those concerned by decelerating growth, insider departures, and the reliance on price hikes.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community debates a potential short squeeze and breakout toward double digits, fueled by analyst upgrades and positive sentiment surrounding the upcoming ES9 flagship SUV. Investors are actively discussing the stock's consolidation, with many focusing on battery-swapping technology as a key long-term differentiator against industry competitors.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical Ltd. is experiencing high volatility as investors react to the company's recent reverse stock split and ongoing speculation surrounding potential government-backed research initiatives. The stock has become a primary focus for community discussions regarding low-float dynamics and potential short-squeeze setups, with traders actively monitoring its price action against sector peers.

Operates as a holding company with interest in providing social shopping platform solutions

WeShop Holdings Ltd - Ordinary Shares - Class A

WeShop Holdings Limited

WeShop Holdings is currently capturing investor attention as a high-volatility, low-float play that traders are actively targeting for aggressive short squeeze potential. Community sentiment remains polarized, with retail participants closely tracking the stock's massive intraday swings while debating whether the recent upward momentum is a sustainable breakout or a classic pump-and-dump cycle.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging to all-time highs as investors digest a price target upgrade and positive sentiment surrounding the company's expanding AI infrastructure deals, including a significant partnership in France. While community members are actively debating whether this is a sustainable breakout or a temporary pump, discussion is heavily focused on AMD's potential to become a primary competitor to Nvidia and its trajectory toward long-term valuation growth.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is capturing significant investor attention as it prepares for the high-stakes launch of its BlueBird 7 satellite, a critical milestone for validating its space-based cellular broadband network. While the community is actively debating the stock's volatility and the competitive implications of Amazon's recent satellite-related acquisitions, bullish investors are highlighting the company's patent moat and tier-one partnerships as key drivers for long-term growth despite near-term technical and launch-related uncertainty.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is experiencing significant market attention as investors weigh its role in next-generation AI data center infrastructure against the company's long-term performance and lack of high-profile contract announcements. While bulls highlight recent product innovations and potential for a short squeeze, skeptics are actively debating insider selling activity and the stock's tendency to face repeated consolidation cycles.

Based is a financial superapp built on Hyperliquid that lets users trade crypto, equities, and commodities from a single interface, fund accounts directly from bank accounts or credit cards, and spend balances at over 100 million merchants worldwide using a Visa Platinum card that converts at the point of sale with no separate off-ramp required. The platform operates across web, iOS, Android, and desktop with one account, and includes features like curated Launchpools for early project access and AI-native wallets for autonomous trading and risk monitoring.

Based Token

$BASED is experiencing extreme volatility characterized by sharp price swings and intense debate among investors over whether the token is a legitimate high-growth asset or prone to manipulation. While some community members remain bullish on its potential within the Base ecosystem, others are actively warning about liquidity concerns and the risk of rapid sell-offs.

Maulcoin

Maulcoin is currently trending as its community of "Maulers" actively rallies against market volatility and attempts to push the token toward higher market capitalization milestones. Enthusiasts are engaging in "Maul challenges" and social media campaigns to maintain momentum, while simultaneously navigating and rejecting competing meme coin projects they view as clones or malicious actors.

The Last Play is Crypto’s 401k.  RETIRE is more than a coin; it’s The Last Play. We are a community dedicated to breaking free from the grind and building true generational wealth. With RETIRE, our mission is simple yet profound: to provide a pathway to retire yourself and secure financial freedom for your bloodline. While others chase hype and trends, we’re focused on creating a legacy that lasts beyond the typical cycle. RETIRE is about making the one move that matters, with a vision for long-term value, freedom, and impact. This isn’t just a meme —it’s a purpose-driven commitment to building a legacy.

The Last Play

The RETIRE token is gaining traction as a community-driven movement aimed at providing an alternative to traditional retirement funds. Supporters are actively promoting it as a long-term hold and building momentum through organized buying campaigns, positioning the token as a way to achieve financial independence.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Equities Analysts Offer Predictions for UNCY Q1 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Analysts at Brookline Capital Markets issued their Q1 2026 earnings per share estimates for Unicycive Therapeutics in a research note issued on Tuesday, April 7th. Brookline Capital Markets analyst K. Raja expects that the company will post...

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Moderate Buy" by Brokerages

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assi...

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, April 9, 2026 NEW YORK, April 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...

Brookline Capital Markets Estimates UNCY Q2 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Brookline Capital Markets issued their Q2 2026 earnings per share estimates for shares of Unicycive Therapeutics in a report issued on...

Benchmark Cuts Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $15.00

Benchmark lowered their target price on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a "speculative buy" rating for the company in a research note on Monday...

HC Wainwright Issues Positive Estimate for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 EPS estimates for Unicycive Therapeutics in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst S. Ramakanth now anticipates that the company will post...

Guggenheim Has Lowered Expectations for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price

Guggenheim decreased their price target on Unicycive Therapeutics from $46.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday...

Noble Financial Has Positive Forecast for UNCY Q1 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at Noble Financial increased their Q1 2026 earnings per share (EPS) estimates for shares of Unicycive...

<ul class="summary-bullets"><li>The FDA is expected to decide on the application by June 29, as per the company.&nbsp;</li><li>The FDA in June refused to approve the company’s application citing manufacturing issues at a third-party manufacturing vendor.&nbsp;</li><li>The company is now looking to launch OLC in the third quarter.</li></ul>Shares of Unicycive Therapeutics Inc (UNCY) jumped 9% on Wednesday as retail investors contemplated the possibility of approval for the company’s Oxylanthanum carbonate.UNCY has resubmitted its application seeking the U.S. Food and Drug Administration’s approval for Oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis following a previous rejection. The FDA is expected to decide on the application by June 29, as per the company.The FDA in June refused to approve the company’s application citing manufacturing issues at a third-party manufacturing vendor.The company is now looking to launch OLC in the third quarter and is continuing to strengthen its commercial infrastructure and advance market readiness initiatives in the meantime.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around UNCY jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels. Over the past week, message volume rose 150%, according to Stocktwits data.A Stocktwits user predicted revenue of as much as $600 million for OLC in 2029.<stembedurl>https://www.stocktwits.com/Thrasher5699/message/649190093</stembedurl>Yet another sees 80% chances for the drug’s approval this time.<stembedurl>https://www.stocktwits.com/Cvfiore2001/message/649096819</stembedurl><h2 class="st-heading-2">Unicycive Therapeutics Inc Management Commentary</h2>“This year is shaping up to be pivotal for Unicycive, underscored by the U.S. Food and Drug Administration’s acceptance of our New Drug Application resubmission for OLC and the potential for approval and launch later this year,” said CEO Shalabh Gupta earlier this week. “With hyperphosphatemia still uncontrolled in nearly 75% of U.S. patients with chronic kidney disease undergoing dialysis, OLC, if approved, has the potential to offer a meaningful new treatment option characterized by a differentiated clinical profile and reduced pill burden compared to currently available phosphate binders.”Hyperphosphatemia is a condition characterized by excessively high levels of phosphate in the blood.<a href="https://stocktwits.com/symbol/UNCY">UNCY stock </a>has gained nearly 32% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lly-stock-rallies-on-much-awaited-fda-approval-for-weight-loss-pill/cZ7Hp5ORIF5">LLY Stock Rallies On Much Awaited FDA Approval For Weight Loss Pill</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.<div class="st-video-embed" data-video-url="https://videos.stocktwits-cdn.com/hls/2026/03/26/69ee8298-8c28-42e1-b686-43e84dc29610/fq6gh7vs9vzzy7rkkx2fll5vlsu3_download.mp4" data-thumbnail-url="" data-caption="" data-summary="" data-width="" data-height="" data-orientation="horizontal" data-duration="">&nbsp;</div>

Rising stock market chart on a trading board background.

UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval

UNCY has resubmitted its application seeking the U.S. Food and Drug Administration’s approval for Oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. 

Equity

UNCY has resubmitted its application seeking the U.S. Food and Drug Administration’s approval for Oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. 


Noble Financial Brokers Boost Earnings Estimates for UNCY

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Stock analysts at Noble Financial increased their Q3 2026 earnings per share estimates for Unicycive Therapeutics in a research report...

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Current Price	$6.90
Prev Close	$6.97
Open	$6.97
Dividend Yield	0.00%
50-Day Moving Average	$6.67
Beta	0.79
Avg. Volume	456,861.01
PE Ratio	-3.45

52-Week High	$11.00
52-Week Low	$3.71
Market Capitalization	$175.91M
EPS (Annual)	-$1.67
Price to Book	5.10
Revenue Per Employee	$0.00

UNCY
Unicycive Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest UNCY News

UNCYUnicycive Therapeutics Inc